Results 211 to 220 of about 964,371 (305)

CD28‐Targeted Enzyme‐Responsive Conformation‐Switching Peptide Self‐Assembly for Selective T‐Cell Acute Lymphoblastic Leukemia (T‐ALL) Therapy

open access: yesAdvanced Science, EarlyView.
We developed the enzyme‐responsive peptide SAp‐CD28 to selectively target CD28‐overexpressing T‐ALL cells. Following phosphatase‐mediated activation, SAp‐CD28 undergoes conformational switching and nanooligomerization, resulting in the disruption of CD28 downstream signaling.
Jun Li   +10 more
wiley   +1 more source

Enzymatic DNA Reaction Networks for Orchestrating Stimuli‐Dependent Temporal Molecular Pulse

open access: yesAdvanced Science, EarlyView.
We present an enzymatic DNA reaction network (EDRN) that encodes nucleic‐acid targets in time, converting inputs into a universal strand and then into programmable transient fluorescence pulses. With time‐color multiplexing, EDRN enables single‐tube high‐plex nucleic acid detection and shows strong agreement with clinical sequencing across 32 specimens.
Jiayu Yang   +7 more
wiley   +1 more source

Dual‐Targeting Cuproptosis and Mitophagy via a Flavopiridol‐Copper Nanoplatform Potentiates Immunotherapy Against Uveal Melanoma

open access: yesAdvanced Science, EarlyView.
This study develops a GSH‐responsive nanoplatform, NP@Fla‐Cu, to co‐activate cuproptosis and excessive mitophagy in uveal melanoma. The nanoplatform enhances tumor‐specific copper delivery, depletes antioxidant defenses, and remodels the tumor immune microenvironment.
Hong Ren   +5 more
wiley   +1 more source

HPLC, chatecholamines

open access: yesJournal of Life Support Technology, 1991
openaire   +2 more sources

Multi‐Targeting Non‐Specific Genome Engineering in Bacteria

open access: yesAdvanced Science, EarlyView.
In this study, we provide the first case to use the multi‐targeting integrase (MTI) systems in bacteria and develop a host‐independent generalizable approach, MNGE (Multi‐targeting Non‐specific Genome Engineering), for multi‐copy and random integration of metabolic genes or pathways in both Gram‐positive and Gram‐negative bacteria, which will ...
Runze Sun   +7 more
wiley   +1 more source

First Generation Proteolysis Targeting Chimeras (PROTACs) for the Treatment of Progeria

open access: yesAdvanced Science, EarlyView.
We report the first PROTACs designed to degrade progerin, introducing a novel therapeutic approach for progeria. The best compound, UCM‐18142, significantly reduces progerin levels and improves key disease phenotypes in patient‐derived cells and in the LmnaG609G/G609G mouse model, paving the way for new treatment strategies targeting the root cause of ...
Jon Macicior‐Michelena   +5 more
wiley   +1 more source

Home - About - Disclaimer - Privacy